BIENAIME JEAN JACQUES purchased $11K of KROS
BIENAIME JEAN JACQUES purchased 1,000 shares of Keros Therapeutics, Inc. (KROS) at $10.61 on 2026-07-15 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The only new information is the director’s small open-market purchase details and post-transaction holdings; it does not introduce new guidance, trial results, or corporate actions.
Market read
Useful for monitoring insider activity, but unlikely to drive a tradable repricing without accompanying fundamental news.
What to watch
The filing does not disclose any new operational, clinical, or financial information; traders should not treat it as a proxy for near-term catalysts.
Background
The article is an SEC Form 4 insider transaction disclosure for Keros Therapeutics, Inc.
Ticker impact
Keros Therapeutics director BIENAIME JEAN JACQUES bought 1,000 shares at $10.61 on 2026-07-15 under a 10b5-1 plan, per Form 4.
Likely limited immediate price impact; any effect is second-order and sentiment-driven.
The filing is primary-source but the disclosed transaction size ($10,610) is modest and explicitly tied to a pre-arranged 10b5-1 plan, reducing signal strength.
Market effects
No direct sector read-through; this is an individual insider transaction without new company fundamentals.
None indicated.
None indicated.
Counterpoint
Because the purchase is under a 10b5-1 plan and is relatively small, it may reflect scheduled liquidity rather than a strong conviction signal.
Key entities
- issuerKeros Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderBIENAIME JEAN JACQUES
Director who reported the open-market purchase under a 10b5-1 plan.